今日观察！A Wave of "Kete Valuation" Sweeps Through the Market: 50 Stocks Poised for Strong Growth

A Wave of "Kete Valuation" Sweeps Through the Market: 50 Stocks Poised for Strong Growth

Shanghai, China - June 17, 2024 - A recent surge in investor sentiment towards growth stocks, particularly in the healthcare and technology sectors, has been dubbed the "Kete Valuation" phenomenon, named after the Chinese pharmaceutical company C-Bridge (6160.HK). This trend is reminiscent of the "CATL Valuation" rally that occurred in 2021, driven by the strong performance of Contemporary Amperex Technology Co., Ltd. (300015.SZ).

The "Kete Valuation" is characterized by a sharp increase in the share prices of companies with promising growth prospects, often defying broader market trends. This is evident in the recent performance of 50 stocks identified by analysts as having significant growth potential. These stocks, spanning various industries including healthcare, technology, and consumer goods, have exhibited remarkable resilience amidst recent market volatility.

Factors Driving the "Kete Valuation"

Several factors are contributing to the "Kete Valuation" trend. Firstly, investors are increasingly seeking out companies that can deliver sustainable growth, particularly in the face of global economic uncertainties. Secondly, the easing of monetary policy in major economies is providing a supportive backdrop for riskier assets like growth stocks. Additionally, advancements in technology and innovation are creating new opportunities for companies in various sectors, fueling investor optimism.

Key Beneficiaries of the "Kete Valuation"

Among the 50 stocks identified as potential beneficiaries of the "Kete Valuation," C-Bridge (6160.HK) stands out as a frontrunner. The company's innovative cancer therapies and strong pipeline of new drugs have attracted significant investor interest. Other notable stocks include:

• Ascletis Pharma (1672.HK): A clinical-stage biopharmaceutical company developing novel therapies for cancer and viral diseases.

• Aier Eye Hospital Group (300015.SZ): A leading provider of comprehensive eye care services in China.

• Xiaomi Corporation (1810.HK): A global technology company known for its smartphones, smart home devices, and internet services.

Investment Implications

The "Kete Valuation" presents an opportunity for investors to capitalize on the growth potential of select companies. However, careful due diligence is crucial, as not all growth stocks are created equal. Investors should thoroughly evaluate a company's financial health, competitive landscape, and long-term growth prospects before making investment decisions.

The "Kete Valuation" highlights the evolving dynamics of the Chinese stock market, where investors are increasingly discerning and seeking out companies with genuine growth potential. This trend is likely to continue as China's economy transitions towards a more innovation-driven and knowledge-based model.

美联储决议落地：市场依旧押注9月降息

北京时间2024年6月13日晚，美国联邦储备委员会（美联储）结束了本月的议息会议，宣布维持联邦基金利率目标区间在5.25%至5.5%不变。 这是美联储连续第七次维持利率不变，符合市场预期。

然而，美联储对今年降息的预期却发生了转变。 美联储最新公布的点阵图显示，19名参与会议的委员中，仅有5人预计今年会降息一次，而7人预计不会降息。这与上次会议的预期存在较大差异，当时有11名委员预计今年至少降息一次。

尽管美联储释放了鹰派信号，但市场却依然押注降息。 隔夜美国股债齐涨，两年期美债收益率下跌多达17个基点至4.67%的低位，标普500指数最高上涨1.3%。

市场押注降息的原因主要有以下几点：

• 5月CPI数据显示美国通胀有所降温。 核心CPI同比增速降至3.9%，为一年多来的低点。这降低了市场对美联储继续加息的预期。
• 美联储主席鲍威尔在会后的新闻发布会上表示，美联储将继续关注通胀数据，并在必要时调整政策。 这被市场解读为美联储有可能在未来转鸽。
• 一些经济学家认为，美联储过度加息可能会导致经济衰退。 因此，他们认为美联储即使要降息，也可能会推迟到今年晚些时候。

总体而言，美联储的决议并没有改变市场对未来降息的预期。 市场依然认为美联储将在今年晚些时候降息，以刺激经济增长。

以下是一些分析人士对美联储决议的看法：

• “美联储的声明仍然鹰派，但市场显然并不买账。” - 彭博策略师Cameron Crise
• “美联储可能低估了市场对降息的预期。” - 摩根大通首席经济学家Michael Feroli
• “美联储最终可能会在今年降息，但前提是通胀继续下降。” - 德意志银行经济学家Matthew Luzzetti

美联储的下一步行动将取决于经济数据和通胀走势。 如果通胀继续下降，美联储可能会在今年晚些时候开始降息。但如果通胀出现反弹，美联储则可能会继续维持高利率政策。